Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 4/20 | 0.72 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.72 |
| ▸ | CDK4 | P11802 | 16/20 | 0.61 |
| ▸ | CCND1 | P24385 | 15/20 | 0.61 |
| ▸ | CCND2 | P30279 | 10/20 | 0.61 |
| ▸ | CCND3 | P30281 | 10/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.61 |
| ▸ | CDK2 | P24941 | 5/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711031 | 0.90 | MARK3 (0.79) | MARK3MARK4CDK4CCND1CCND2 | |
| SCHEMBL22164911 | 0.87 | CDK4 (0.56) | MARK3MARK4CDK4CCND1CCND2 | |
| SCHEMBL19474471 | 0.86 | CDK4 (0.57) | MARK3MARK4CDK4CCND1CCND2 | |
| Hydrochloric Acid SCHEMBL20740457 | 0.85 | CDK4 (0.57) | MARK3MARK4CDK4CCND1CCND2 | |
| SCHEMBL7712932 | 0.82 | MARK3 (0.53) | MARK3MARK4CDK4CCND1CCND2 | |
| SCHEMBL14681922 | 0.82 | MARK3 (0.53) | MARK3MARK4CDK4CCND1CCND2 | |
| SCHEMBL19474313 | 0.82 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL19474311 | 0.82 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CCNA2 | |
| Hydrochloric Acid SCHEMBL20740462 | 0.81 | CDK4 (0.56) | CDK4CCND1CCND2CCND3CCNA2 | |
| Hydrochloric Acid SCHEMBL20740434 | 0.81 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG (CH) | 2018-07-26 | — | — | US | disclosed |
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG (CH) | 2018-07-26 | — | — | US | disclosed |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | NOVARTIS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | NOVARTIS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011130232-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | CDK4, CDK6, CDK8 | MARK3 1010/4885MARK4 292/4885CDK4 1/4885 |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | MARK3 1160/4885MARK4 829/4885CDK4 4/4885 |
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | CDK4, CDK6, MTOR | MARK3 1148/4885MARK4 1018/4885CDK4 1/4885 |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | CDK4, CDK6, CDKL4 | MARK3 1030/4885MARK4 295/4885CDK4 1/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | MARK3 1160/4885MARK4 829/4885CDK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.